Physician profile
Siamak Tabib
NPI 1063555845
$7,309.81
in general payments reported to CMS, 2019-2025
35 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,854 · 2020: $786 · 2021: $551 · 2022: $817 · 2023: $1,165 · 2024: $1,081 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,161 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,160.86 |
| Education | $141.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,223.85 | 2019-2025 | Skyrizi, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,012.74 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $758.18 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $717.64 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $371.43 | 2019-2025 | |
| Romark Laboratories, Lc | $251.12 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $245.11 | 2024-2025 | Vowst, Zenpep |
| Nestle Healthcare Nutrition INC. | $212.01 | 2021-2023 | |
| Qol Medical, LLC | $175.92 | 2021-2024 | Sucraid, Sucraid |
| Edwards Lifesciences Corporation | $145.83 | 2023-2025 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $144.94 | 2019-2024 | Dificid |
| Daiichi Sankyo INC. | $132.97 | 2019-2023 | Injectafer |
| Lilly USA, LLC | $119.36 | 2024 | Omvoh |
| Ironwood Pharmaceuticals, INC | $93.95 | 2019-2024 | Linzess |
| Novartis Pharmaceuticals Corporation | $77.80 | 2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $74.59 | 2023-2025 | Livmarli |
| Regeneron Healthcare Solutions, INC. | $73.14 | 2024-2025 | Dupixent |
| Braintree Laboratories, INC. | $68.36 | 2019 | |
| Vivus LLC | $45.93 | 2025 | Pancreaze |
| Amgen INC. | $34.78 | 2022 | |
| Allergan, INC. | $30.42 | 2019 | |
| Alfasigma USA, INC. | $30.12 | 2020 | |
| Celgene Corporation | $29.31 | 2023 | Zeposia |
| Genzyme Corporation | $28.45 | 2023 | |
| Capsovision, INC. | $26.74 | 2025 | Capsocam Plus |
| Madrigal Pharmaceuticals | $26.33 | 2024 | Resmetirom |
| Alnylam Pharmaceuticals INC. | $22.18 | 2024 | Amvuttra |
| Dova Pharmaceuticals | $20.85 | 2019 | |
| Concordia Pharmaceuticals INC. | $20.00 | 2019 | |
| Gilead Sciences, INC. | $19.92 | 2019 | |
| Boston Scientific Corporation | $18.51 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.11 | 2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $14.69 | 2019 | |
| Shionogi INC | $12.65 | 2020 | |
| Medtronic, INC. | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siamak Tabib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.